시장보고서
상품코드
1439068

골다공증 치료 및 골절 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회 및 예측 : 약물 유형별, 투여 경로별, 유통 채널별, 지역별, 경쟁사별(2018-2028년)

Anti Osteoporosis Therapy and Fracture Healing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 190 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 골다공증 치료 및 골절 치료 시장은 2022년 140억 2,000만 달러로 평가되었고, 2028년까지 연평균 3.14%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 꾸준한 성장이 예상됩니다.

골다공증은 뼈의 약화를 특징으로 하는 광범위한 골격계 질환으로 골절의 위험을 증가시키고 골절 치료의 합병증을 유발합니다. 골다공증은 특히 세계 인구의 고령화 추세에 따라 전 세계적으로 큰 건강 문제로 대두되고 있습니다. 전 세계 골다공증 치료 및 골절 치료 시장은 의료 전문가, 제약사, 의학 연구자들이 이 쇠약해진 상태에 맞서기 위해 노력하면서 괄목할 만한 성장과 혁신을 목격하고 있습니다. 골다공증은 골절이 발생할 때까지 자각증상 없이 진행되기 때문에 종종 '침묵의 질병'이라고 불립니다. 골다공증에 걸리면 뼈는 밀도와 강도를 잃고 다공성이며 부서지기 쉬워집니다. 그 결과, 특히 고관절, 척추, 손목에서 골절이 발생하기 쉽다. 골다공증은 주로 폐경기 이후 여성에게 많이 발생하지만, 남성이나 모든 연령대의 사람들에게도 영향을 미칠 수 있습니다.

시장 개요
예측 기간 2024-2028년
시장 규모 : 2022년 140억 2,000만 달러
시장 규모 : 2028년 167억 6,000만 달러
2023-2028년 CAGR 3.14%
급성장 부문 칼시토닌
최대 시장 북미

이 시장에서는 약물치료, 의료기기, 수술, 생활습관 개선 등 다양한 치료 옵션이 제공되고 있습니다. 이러한 옵션은 골다공증 치료뿐만 아니라 골절 후 치유 과정을 향상시키는 것을 목표로 합니다. 최소 침습 수술 기술, 재생 치료와 같은 첨단 기술은 골다공증 치료 및 골절 치료의 효과를 높이고 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 골다공증 치료 및 골절 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 유형별(칼시토닌, 비스포스포네이트, 호르몬 대체요법, 아나볼릭, 기타)
    • 투여 경로별(경구, 주사)
    • 유통 채널별(병원 약국, 소매 약국, E-Commerce)
    • 지역별
    • 기업별(2022년)
  • 시장 맵
    • 약제 유형별
    • 투여 경로별
    • 유통 채널별
    • 지역별

제5장 아시아태평양의 골다공증 치료 및 골절 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 유형별
    • 투여 경로별
    • 유통 채널별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 골다공증 치료 및 골절 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 유형별
    • 투여 경로별
    • 유통 채널별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 골다공증 치료 및 골절 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 유형별
    • 투여 경로별
    • 유통 채널별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 골다공증 치료 및 골절 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 유형별
    • 투여 경로별
    • 유통 채널별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 골다공증 치료 및 골절 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 유형별
    • 투여 경로별
    • 유통 채널별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

제12장 세계의 골다공증 치료 및 골절 치료 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

제14장 경쟁 구도

  • GlaxoSmithKline plc
  • Medtronic Plc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd
  • Stryker Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Orthofix US LLC

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.04.08

Global Anti Osteoporosis Therapy and Fracture Healing Market was valued at USD 14.02 Billion in 2022 and is anticipated to project steady growth in the forecast period with a CAGR of 3.14% through 2028. Osteoporosis is a pervasive skeletal disorder characterized by weakened bones, increasing the risk of fractures and, subsequently, fracture healing complications. This condition poses a significant global health challenge, especially as the world's population continues to age. The global anti-osteoporosis therapy and fracture healing market has been witnessing remarkable growth and innovation as healthcare professionals, pharmaceutical companies, and medical researchers seek to combat this debilitating condition. Osteoporosis is often referred to as the 'silent disease' because it progresses without symptoms until a fracture occurs. In osteoporotic individuals, bones lose their density and strength, becoming more porous and fragile. This results in a higher susceptibility to fractures, particularly in the hip, spine, and wrist. Osteoporosis predominantly affects postmenopausal women, but it can also impact men and individuals of all ages.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 14.02 Billion
Market Size 2028USD 16.76 Billion
CAGR 2023-20283.14%
Fastest Growing SegmentCalcitonin
Largest MarketNorth America

The market offers a diverse range of treatment options, including medications, medical devices, surgical procedures, and lifestyle modifications. These options aim to not only treat osteoporosis but also enhance the healing process after a fracture. Cutting-edge technologies, such as minimally invasive surgical techniques and regenerative therapies, are enhancing the effectiveness of osteoporosis treatment and fracture healing.

Key Market Drivers

Rising Aging Population is Driving the Global Anti Osteoporosis Therapy and Fracture Healing Market

The global healthcare landscape is undergoing a significant transformation, largely driven by the aging population. As people live longer, they are more likely to experience age-related health issues, one of the most common being osteoporosis. This bone disease, characterized by decreased bone density and increased fragility, poses a considerable threat to the elderly, resulting in fractures that can have debilitating consequences. The rising aging demographic has given rise to a thriving market for anti-osteoporosis therapy and fracture healing solutions.

The world's population is aging at an unprecedented rate. Advancements in healthcare, nutrition, and lifestyle choices have led to increased life expectancy. This demographic shift is observed across developed and developing countries alike, albeit at varying rates. According to the United Nations, by 2050, the global population aged 60 and above will surpass 2 billion, accounting for more than 20% of the total population. As individuals age, their bone density naturally decreases. This gradual weakening of the bones is a significant factor behind the increased prevalence of osteoporosis. Osteoporosis is often referred to as a "silent disease" because it progresses without obvious symptoms until a fracture occurs. Fractures, especially hip fractures, can have devastating consequences for the elderly, leading to reduced mobility, chronic pain, and increased mortality rates.

Growing awareness about osteoporosis and its implications on bone health has encouraged individuals to seek early diagnosis and treatment. This has driven the demand for anti-osteoporosis therapies. The development of innovative diagnostic tools and therapeutic options for osteoporosis has improved the treatment landscape. This includes medications to strengthen bones and reduce fracture risk, as well as cutting-edge surgical techniques for fracture healing. Public and private research organizations, along with pharmaceutical companies, are investing heavily in osteoporosis research. This collaboration has led to a better understanding of the disease and the development of more effective treatments.

Increasing Prevalence of Osteoporosis is Driving the Global Anti Osteoporosis Therapy and Fracture Healing Market

The increasing prevalence of osteoporosis has created a significant demand for anti-osteoporosis therapies and fracture healing solutions. This demand has spurred innovation and investment in the healthcare industry, resulting in a rapidly growing market for products and services addressing osteoporosis prevention, diagnosis, and treatment. Fractures associated with osteoporosis have substantial health and economic consequences. Hip fractures, for instance, are associated with a high mortality rate and often lead to long-term disability. Spinal fractures can result in chronic back pain, postural changes, and decreased mobility. Wrist fractures, while less severe, can still impact a person's independence and quality of life. The economic costs of treating these fractures are substantial, including hospitalization, surgery, rehabilitation, and long-term care.

Osteoporosis is more prevalent in women, especially post-menopausal women, due to hormonal changes that affect bone density. This gender disparity further fuels the growing prevalence of osteoporosis. In developing countries, where life expectancy is increasing, the burden of osteoporosis in women is likely to rise significantly.

Pharmaceutical companies have developed a range of medications that help to slow bone loss, increase bone density, and reduce fracture risk. These medications, such as bisphosphonates, selective estrogen receptor modulators (SERMs), and monoclonal antibodies, are widely prescribed for osteoporosis management. Advances in diagnostic technologies have made it easier to identify individuals at risk of osteoporosis. Dual-energy X-ray absorptiometry (DXA) scans are commonly used to measure bone density. These tools enable healthcare providers to diagnose osteoporosis early and implement interventions. In cases where fractures have already occurred, surgical solutions, such as vertebroplasty and kyphoplasty for spinal fractures, are available to provide pain relief and improve patients' quality of life. Nutrition plays a crucial role in maintaining bone health. The market for calcium and vitamin D supplements is expanding as people seek ways to support their bone density through diet and supplementation. Increasing awareness about osteoporosis and the importance of early detection and prevention has led to the development of educational campaigns and resources.

Key Market Challenges

Aging Population

One of the most significant challenges facing the market is the global aging population. As people live longer, the prevalence of osteoporosis and fractures increases. The demand for effective therapies and fracture healing solutions is surging, leading to a strain on healthcare systems and resources. This challenge necessitates the development of cost-effective and scalable treatments to meet the growing demand.

High Cost of Medications

Many anti-osteoporosis medications are expensive, making them inaccessible to a large portion of the population, especially in low- and middle-income countries. The high cost of these medications often results in delayed or inadequate treatment, which can lead to more severe health issues. Developing affordable alternatives and expanding access to these medications is a key challenge for the industry.

Lack of Awareness

Awareness about osteoporosis and fracture healing is a critical factor in early diagnosis and treatment. However, many individuals, particularly in developing countries, lack awareness about these conditions. Education and public health campaigns are essential to increase awareness, but they face hurdles in reaching remote or underprivileged communities.

Regulatory Hurdles

The development and approval of new drugs and medical devices are subject to strict regulatory processes, which can be time-consuming and expensive. Navigating these regulatory hurdles can be a major challenge for companies in the anti-osteoporosis and fracture healing market. Delays in approvals can impede the introduction of potentially life-changing therapies.

Side Effects and Efficacy

Despite advancements in drug development, some anti-osteoporosis medications come with side effects, which can deter patients from using them or lead to discontinuation. Striking a balance between efficacy and safety is a persistent challenge in this market. Additionally, not all individuals respond equally to treatments, which makes personalization a crucial aspect that researchers are trying to address.

Limited Treatment Options

While there have been significant developments in osteoporosis treatments, the market still lacks a broad range of options. This limited diversity in available therapies leaves healthcare providers with fewer choices for tailoring treatments to individual patient needs. Diversifying treatment options and exploring alternative therapies like non-pharmacological interventions remains a challenge.

Healthcare Disparities

Healthcare disparities in different regions of the world pose a significant challenge to the global anti-osteoporosis and fracture healing market. Access to healthcare, including diagnosis and treatment options, varies greatly from one region to another. Bridging these disparities and ensuring equitable access to care is a complex challenge.

Research and Development Costs

Developing new drugs, therapies, and medical devices for osteoporosis and fracture healing is expensive and time-consuming. The high costs of research and development can be a limiting factor for smaller pharmaceutical and biotech companies. Finding innovative ways to reduce R&D costs is a constant challenge for the industry.

Key Market Trends

Technological Advancements

Technological advancements have revolutionized the diagnosis of osteoporosis. Traditional methods, such as X-rays, while still valuable, have limitations. Dual-energy X-ray absorptiometry (DXA) scans are now widely used for bone density measurements, enabling early detection of osteoporosis. Furthermore, portable and cost-effective devices that use ultrasound to measure bone density are becoming increasingly accessible, allowing for early screening in primary care settings. Imaging technologies like magnetic resonance imaging (MRI) and computed tomography (CT) scans have evolved to provide better visualization of bone structure, helping doctors detect fractures and monitor healing. Three-dimensional printing and modeling have also made significant strides, allowing for the creation of personalized implants and prosthetics for patients with complex fractures. Pharmaceutical companies are investing in innovative drug development to combat osteoporosis. Targeted therapies, such as monoclonal antibodies and selective estrogen receptor modulators, are becoming available, offering a more specific and effective approach to treatment. Additionally, genetic testing and personalized medicine are contributing to the development of tailored treatment plans based on individual patients' genetics, lifestyle, and risk factors.

Telemedicine and digital health solutions are playing a crucial role in osteoporosis management. Patients can now access consultations with specialists remotely, ensuring timely and efficient care. Wearable devices and mobile apps provide tools for monitoring bone health, encouraging adherence to therapy regimens, and enabling real-time data transmission to healthcare providers for a more comprehensive approach to care. In the field of fracture healing, surgical techniques have advanced significantly. Minimally invasive procedures, such as arthroscopy, have reduced recovery times and complications associated with surgery. In orthopedics, advancements in implant materials and design have improved the success rates of joint replacements, enhancing the quality of life for patients.

The development of regenerative medicine approaches for fracture healing is a promising avenue. Stem cell therapies, tissue engineering, and growth factors are being explored to accelerate the body's natural healing processes. These techniques aim to not only repair the bone but also restore its functionality, reducing the risk of long-term complications. Artificial intelligence (AI) and data analytics are enhancing disease prediction, diagnosis, and treatment outcomes in osteoporosis. Machine learning algorithms can analyze large datasets to identify high-risk individuals and predict fractures, enabling early intervention. AI is also used to optimize drug discovery processes, potentially leading to more effective treatments.

Segmental Insights

Drug Type Insights

Based on the category of Drug Type, Calcitonin emerged as the dominant player in the global market for Anti Osteoporosis Therapy and Fracture Healing in 2022. Calcitonin is a hormone produced by the thyroid gland and plays a vital role in regulating calcium levels in the body. In the context of osteoporosis, calcitonin is particularly noteworthy for its ability to inhibit bone resorption, which is the process by which old bone tissue is broken down and replaced with new bone. This mechanism makes calcitonin a crucial component of anti-osteoporosis therapy, as it helps to preserve bone mass and prevent fractures. Numerous studies have demonstrated the effectiveness of calcitonin in slowing down bone loss and reducing the risk of fractures, making it a trusted choice for healthcare professionals. Its ability to maintain bone density and strength is a vital factor in its dominance. Calcitonin is well-tolerated by most patients and is associated with minimal side effects. This is particularly important in a market where patient comfort and safety are of utmost concern. Calcitonin is available in various administration forms, including injection, nasal spray, and oral formulations, making it suitable for a wide range of patient preferences and needs.

Distribution Channel Insights

The Hospital Pharmacies segment is projected to experience rapid growth during the forecast period. Hospital pharmacies are staffed with trained pharmacists who possess specialized knowledge about osteoporosis medications. This expertise enables them to provide guidance to healthcare professionals and patients, ensuring that the right medication is prescribed and administered correctly. Additionally, hospital pharmacies are readily accessible to patients who are already in the hospital for various reasons, making it convenient for them to receive osteoporosis treatment. Hospital pharmacies bridge the gap between inpatient and outpatient care. Patients who have undergone surgery due to fractures caused by osteoporosis often require postoperative care and rehabilitation. Hospital pharmacies can seamlessly transition patients from inpatient treatment to outpatient care, ensuring they continue their osteoporosis therapy as needed. The management of osteoporosis medication is a crucial aspect of treatment success. Hospital pharmacies closely monitor patient medication regimens, help manage side effects, and ensure adherence. This level of oversight enhances patient outcomes and reduces the risk of fractures.

Regional Insights

North America emerged as the dominant player in the global Anti Osteoporosis Therapy and Fracture Healing market in 2022, holding the largest market share in terms of value. North America boasts a highly developed healthcare infrastructure with world-class medical facilities, research institutions, and a skilled workforce. This allows for rapid innovation, research, and development of cutting-edge therapies for osteoporosis and fracture healing. The region is home to some of the world's largest pharmaceutical companies. These companies invest heavily in research and development, resulting in the creation of innovative and effective medications and therapies for osteoporosis and fracture healing. The aging population in North America, combined with lifestyle factors such as reduced physical activity and poor dietary habits, has led to a relatively high prevalence of osteoporosis. This prevalence fuels the demand for anti-osteoporosis therapies in the region.

Key Market Players

GlaxoSmithKline plc

Medtronic Plc.

Merck & Co. Inc.

Novartis AG

Pfizer inc.

Eli Lilly and Co.

F. Hoffmann-La Roche Ltd

Stryker Corporation

Teva Pharmaceutical Industries Ltd.

Orthofix US LLC

Report Scope:

In this report, the Global Anti Osteoporosis Therapy and Fracture Healing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti Osteoporosis Therapy and Fracture Healing Market, By Drug Type:

  • Calcitonin
  • Bisphosphonates
  • Hormone Replacement Therapy
  • Anabolic
  • Others

Anti Osteoporosis Therapy and Fracture Healing Market, By Route of Administration:

  • Oral
  • Injectable

Anti Osteoporosis Therapy and Fracture Healing Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Anti Osteoporosis Therapy and Fracture Healing Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Anti Osteoporosis Therapy and Fracture Healing Market.

Available Customizations:

  • Global Anti Osteoporosis Therapy and Fracture Healing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drug Type (Calcitonin, Bisphosphonates, Hormone Replacement Therapy, Anabolic, Others)
    • 4.2.2. By Route of Administration (Oral, Injectable)
    • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Drug Type
    • 4.3.2. By Route of Administration
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. Asia Pacific Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type
    • 5.2.2. By Route of Administration
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Drug Type
        • 5.3.1.2.2. By Route of Administration
        • 5.3.1.2.3. By Distribution Channel
    • 5.3.2. India Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Drug Type
        • 5.3.2.2.2. By Route of Administration
        • 5.3.2.2.3. By Distribution Channel
    • 5.3.3. Australia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Drug Type
        • 5.3.3.2.2. By Route of Administration
        • 5.3.3.2.3. By Distribution Channel
    • 5.3.4. Japan Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Drug Type
        • 5.3.4.2.2. By Route of Administration
        • 5.3.4.2.3. By Distribution Channel
    • 5.3.5. South Korea Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Drug Type
        • 5.3.5.2.2. By Route of Administration
        • 5.3.5.2.3. By Distribution Channel

6. Europe Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Germany Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Spain Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Italy Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Type
        • 6.3.4.2.2. By Route of Administration
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. United Kingdom Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Type
        • 6.3.5.2.2. By Route of Administration
        • 6.3.5.2.3. By Distribution Channel

7. North America Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Mexico Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Canada Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel

8. South America Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Argentina Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Colombia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Saudi Arabia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. UAE Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Anti Osteoporosis Therapy and Fracture Healing Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. GlaxoSmithKline plc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Medtronic Plc.
  • 14.3. Merck & Co. Inc.
  • 14.4. Novartis AG
  • 14.5. Pfizer inc.
  • 14.6. Eli Lilly and Co.
  • 14.7. F. Hoffmann-La Roche Ltd
  • 14.8. Stryker Corporation
  • 14.9. Teva Pharmaceutical Industries Ltd.
  • 14.10. Orthofix US LLC

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제